Archive - Latest News Search Engine - Global and Local Breaking News

Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels

Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Your briefing

Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels

Hybrid closed-loop technology effectively helped women stay in target glucose range for longer compared to standard of care CHICAGO, June 20, 2025 /PR...

Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

New Studies Highlight Machine Learning as Potential Early Risk Detection Strategy CHICAGO, June 20, 2025 /PRNewswire/ -- Developments from two studies...

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from re...

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocr...

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system